Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Cell Metabolism

Volumn 27, Issue 1, 2018, Pages 22-41

  Samuel, Varman T ^a,b   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

diacylglycerol; insulin resistance; liver metabolism; mitochondria; non alcoholic fatty liver disease; non alcoholic steatohepatitis; type 2 diabetes

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; FIBROBLAST GROWTH FACTOR 21; GLUCAGON LIKE PEPTIDE 1; INSULIN; LIPID; MONOCARBOXYLATE TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; GLUCOSE;

BARIATRIC SURGERY; BODY WEIGHT LOSS; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER DISEASE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; PRIORITY JOURNAL; REVIEW; TIGHT JUNCTION; ANIMAL; METABOLISM;

ANIMALS; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85028512852     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.08.002     Document Type: Review

References (255)

1. Abu-Elheiga, L., Wu, H., Gu, Z., Bressler, R., Wakil, S.J., Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. J. Biol. Chem. 287 (2012), 12578–12588.
2. Abulizi, A., Perry, R.J., Camporez, J.P.G., Jurczak, M.J., Petersen, K.F., Aspichueta, P., Shulman, G.I., A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. FASEB J. 31 (2017), 2916–2924.
3. Agarwal, S., Patil, A., Aware, U., Deshmukh, P., Darji, B., Sasane, S., Sairam, K.V., Priyadarsiny, P., Giri, P., Patel, H., et al. Discovery of a potent and orally efficacious TGR5 receptor agonist. ACS Med. Chem. Lett. 7 (2015), 51–55.
4. Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R.J., Reese, C.B., Cohen, P., Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7 (1997), 261–269.
5. Andersson, D.P., Eriksson-Hogling, D., Bäckdahl, J., Thorell, A., Löfgren, P., Rydén, M., Arner, P., Hoffstedt, J., Omentectomy in addition to bariatric surgery—a 5-year follow-up. Obes. Surg. 27 (2017), 1115–1118.
6. Armstrong, M.J., Barton, D., Gaunt, P., Hull, D., Guo, K., Stocken, D., Gough, S.C., Tomlinson, J.W., Brown, R.M., Hübscher, S.G., Newsome, P.N., LEAN trial team. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open, 3, 2013, e003995.
7. Armstrong, M.J., Hull, D., Guo, K., Barton, D., Hazlehurst, J.M., Gathercole, L.L., Nasiri, M., Yu, J., Gough, S.C., Newsome, P.N., Tomlinson, J.W., Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64 (2016), 399–408.
8. Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5 (2007), 426–437.
9. Baldry, E.L., Aithal, G.P., Kaye, P., Idris, I.R., Bennett, A., Leeder, P.C., Macdonald, I.A., Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches. Diabetes Obes. Metab. 19 (2017), 1179–1183.
10. Basantani, M.K., Sitnick, M.T., Cai, L., Brenner, D.S., Gardner, N.P., Li, J.Z., Schoiswohl, G., Yang, K., Kumari, M., Gross, R.W., et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J. Lipid Res. 52 (2011), 318–329.
11. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006), 2297–2307.
12. Bergman, R.N., New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog. Horm. Res. 52 (1997), 359–385 discussion 385–387.
13. Bhatnagar, S., Damron, H.A., Hillgartner, F.B., Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 284 (2009), 10023–10033.
14. Billeter, A.T., Senft, J., Gotthardt, D., Knefeli, P., Nickel, F., Schulte, T., Fischer, L., Nawroth, P.P., Büchler, M.W., Müller-Stich, B.P., Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass?—a controlled matched pair study of 34 patients. Obes. Surg. 26 (2016), 1867–1874.
15. Bindesbøll, C., Fan, Q., Nørgaard, R.C., MacPherson, L., Ruan, H.-B., Wu, J., Pedersen, T.Å., Steffensen, K.R., Yang, X., Matthews, J., et al. Liver X receptor regulates hepatic nuclear O-GlcNAc signaling and carbohydrate responsive element-binding protein activity. J. Lipid Res. 56 (2015), 771–785.
16. Bojic, L.A., Huff, M.W., Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player. Curr. Opin. Lipidol. 24 (2013), 171–177.
17. Bourbeau, M.P., Siegmund, A., Allen, J.G., Shu, H., Fotsch, C., Bartberger, M.D., Kim, K.W., Komorowski, R., Graham, M., Busby, J., et al. Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase. J. Med. Chem. 56 (2013), 10132–10141.
18. Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo-Perez, F., Guy, C.D., Seed, P.C., Rawls, J.F., David, L.A., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63 (2016), 764–775.
19. Bray, G.A., Popkin, B.M., Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: health be damned! Pour on the sugar. Diabetes Care 37 (2014), 950–956.
20. Bricker, D.K., Taylor, E.B., Schell, J.C., Orsak, T., Boutron, A., Chen, Y.C., Cox, J.E., Cardon, C.M., Van Vranken, J.G., Dephoure, N., et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337 (2012), 96–100.
21. Briere, D.A., Ruan, X., Cheng, C.C., Siesky, A.M., Fitch, T.E., Dominguez, C., Sanfeliciano, S.G., Montero, C., Suen, C.S., Xu, Y., et al. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS ONE, 10, 2015, e0136873.
22. Brown, M.S., Goldstein, J.L., Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7 (2008), 95–96.
23. Brown, J.M., Rudel, L.L., Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. Curr. Opin. Lipidol. 21 (2010), 192–197.
24. Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., Grundy, S.M., Hobbs, H.H., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
25. Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H.D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat. Genet. 47 (2015), 1443–1448.
26. Cai, K., Sewer, M.B., Diacylglycerol kinase θ couples farnesoid X receptor-dependent bile acid signalling to Akt activation and glucose homoeostasis in hepatocytes. Biochem. J. 454 (2013), 267–274.
27. Camporez, J.P., Jornayvaz, F.R., Petersen, M.C., Pesta, D., Guigni, B.A., Serr, J., Zhang, D., Kahn, M., Samuel, V.T., Jurczak, M.J., Shulman, G.I., Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154 (2013), 3099–3109.
28. Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S., Suri, V., Qadri, A., Gareski, T., Jones, J., Hahm, S., et al. Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J. Biol. Chem. 286 (2011), 41838–41851.
29. Carino, A., Cipriani, S., Marchianò, S., Biagioli, M., Santorelli, C., Donini, A., Zampella, A., Monti, M.C., Fiorucci, S., BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci. Rep., 7, 2017, 42801.
30. Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., Laville, M., Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 36 (2013), 2923–2930.
31. Chen, W., Chang, B., Li, L., Chan, L., Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 52 (2010), 1134–1142.
32. Chen, Z., Vigueira, P.A., Chambers, K.T., Hall, A.M., Mitra, M.S., Qi, N., McDonald, W.G., Colca, J.R., Kletzien, R.F., Finck, B.N., Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J. Biol. Chem. 287 (2012), 23537–23548.
33. Choi, C.S., Savage, D.B., Kulkarni, A., Yu, X.X., Liu, Z.X., Morino, K., Kim, S., Distefano, A., Samuel, V.T., Neschen, S., et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem. 282 (2007), 22678–22688.
34. Chow, J.D., Lawrence, R.T., Healy, M.E., Dominy, J.E., Liao, J.A., Breen, D.S., Byrne, F.L., Kenwood, B.M., Lackner, C., Okutsu, S., et al. Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol. Metab. 3 (2014), 419–431.
35. Cline, G.W., Petersen, K.F., Krssak, M., Shen, J., Hundal, R.S., Trajanoski, Z., Inzucchi, S., Dresner, A., Rothman, D.L., Shulman, G.I., Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N. Engl. J. Med. 341 (1999), 240–246.
36. Couillard, C., Bergeron, N., Prud'homme, D., Bergeron, J., Tremblay, A., Bouchard, C., Mauriège, P., Després, J.P., Gender difference in postprandial lipemia: importance of visceral adipose tissue accumulation. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 2448–2455.
37. Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165 (2016), 305–315.
38. Cuthbertson, D.J., Steele, T., Wilding, J.P., Halford, J.C., Harrold, J.A., Hamer, M., Karpe, F., What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?. Int. J. Obes. 41 (2017), 853–865.
39. Degirolamo, C., Sabbà, C., Moschetta, A., Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15 (2016), 51–69.
40. Després, J.P., Moorjani, S., Lupien, P.J., Tremblay, A., Nadeau, A., Bouchard, C., Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10 (1990), 497–511.
41. Divakaruni, A.S., Wiley, S.E., Rogers, G.W., Andreyev, A.Y., Petrosyan, S., Loviscach, M., Wall, E.A., Yadava, N., Heuck, A.P., Ferrick, D.A., et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. USA 110 (2013), 5422–5427.
42. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
43. Dresner, A., Laurent, D., Marcucci, M., Griffin, M.E., Dufour, S., Cline, G.W., Slezak, L.A., Andersen, D.K., Hundal, R.S., Rothman, D.L., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103 (1999), 253–259.
44. du Plessis, J., van Pelt, J., Korf, H., Mathieu, C., van der Schueren, B., Lannoo, M., Oyen, T., Topal, B., Fetter, G., Nayler, S., et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology, 149, 2015 635–48.e14.
45. Dushay, J.R., Toschi, E., Mitten, E.K., Fisher, F.M., Herman, M.A., Maratos-Flier, E., Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol. Metab. 4 (2014), 51–57.
46. Edgerton, D.S., Kraft, G., Smith, M., Farmer, B., Williams, P.E., Coate, K.C., Printz, R.L., O'Brien, R.M., Cherrington, A.D., Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion. JCI Insight, 2, 2017, e91863.
47. Erion, D.M., Popov, V., Hsiao, J.J., Vatner, D., Mitchell, K., Yonemitsu, S., Nagai, Y., Kahn, M., Gillum, M.P., Dong, J., et al. The role of the carbohydrate response element-binding protein in male fructose-fed rats. Endocrinology 154 (2013), 36–44.
48. Fabbrini, E., Magkos, F., Mohammed, B.S., Pietka, T., Abumrad, N.A., Patterson, B.W., Okunade, A., Klein, S., Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. USA 106 (2009), 15430–15435.
49. Fabbrini, E., Mohammed, B.S., Korenblat, K.M., Magkos, F., McCrea, J., Patterson, B.W., Klein, S., Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 95 (2010), 2727–2735.
50. Fabbrini, E., Tamboli, R.A., Magkos, F., Marks-Shulman, P.A., Eckhauser, A.W., Richards, W.O., Klein, S., Abumrad, N.N., Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 139 (2010), 448–455.
51. Fan, Y., Lu, H., Guo, Y., Zhu, T., Garcia-Barrio, M.T., Jiang, Z., Willer, C.J., Zhang, J., Chen, Y.E., Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice. Gastroenterology 150 (2016), 1208–1218.
52. Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., Solís-Herruzo, J.A., A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 40 (2008), 200–205.
53. Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. Chemical hybridization of glucagon and thyroid hormone optimizes therapeutic impact for metabolic disease. Cell 167 (2016), 843–857.e14.
54. Flannery, C., Dufour, S., Rabøl, R., Shulman, G.I., Petersen, K.F., Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly. Diabetes 61 (2012), 2711–2717.
55. Francois, M.E., Baldi, J.C., Manning, P.J., Lucas, S.J., Hawley, J.A., Williams, M.J., Cotter, J.D., ‘Exercise snacks’ before meals: a novel strategy to improve glycaemic control in individuals with insulin resistance. Diabetologia 57 (2014), 1437–1445.
56. Froylich, D., Corcelles, R., Daigle, C., Boules, M., Brethauer, S., Schauer, P., Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg. Obes. Relat. Dis. 12 (2016), 127–131.
57. Fuchs, M., Schnabl, B., Editors’ introduction to the NAFLD and NASH special issue. Dig. Dis. Sci. 61 (2016), 1211–1213.
58. Futatsugi, K., Kung, D.W., Orr, S.T., Cabral, S., Hepworth, D., Aspnes, G., Bader, S., Bian, J., Boehm, M., Carpino, P.A., et al. Discovery and optimization of imidazopyridine-based inhibitors of diacylglycerol acyltransferase 2 (DGAT2). J. Med. Chem. 58 (2015), 7173–7185.
59. Gijón, M.A., Riekhof, W.R., Zarini, S., Murphy, R.C., Voelker, D.R., Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils. J. Biol. Chem. 283 (2008), 30235–30245.
60. Golomb, I., Ben David, M., Glass, A., Kolitz, T., Keidar, A., Long-term metabolic effects of laparoscopic sleeve gastrectomy. JAMA Surg. 150 (2015), 1051–1057.
61. Gray, L.R., Sultana, M.R., Rauckhorst, A.J., Oonthonpan, L., Tompkins, S.C., Sharma, A., Fu, X., Miao, R., Pewa, A.D., Brown, K.S., et al. Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis. Cell Metab. 22 (2015), 669–681.
62. Guertin, D.A., Sabatini, D.M., Defining the role of mTOR in cancer. Cancer Cell 12 (2007), 9–22.
63. Gutiérrez-Juárez, R., Pocai, A., Mulas, C., Ono, H., Bhanot, S., Monia, B.P., Rossetti, L., Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest. 116 (2006), 1686–1695.
64. Haas, J.T., Miao, J., Chanda, D., Wang, Y., Zhao, E., Haas, M.E., Hirschey, M., Vaitheesvaran, B., Farese, R.V. Jr., Kurland, I.J., et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 15 (2012), 873–884.
65. Hall, A.M., Kou, K., Chen, Z., Pietka, T.A., Kumar, M., Korenblat, K.M., Lee, K., Ahn, K., Fabbrini, E., Klein, S., et al. Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver. J. Lipid Res. 53 (2012), 990–999.
66. Hall, A.M., Soufi, N., Chambers, K.T., Chen, Z., Schweitzer, G.G., McCommis, K.S., Erion, D.M., Graham, M.J., Su, X., Finck, B.N., Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice. Diabetes 63 (2014), 2284–2296.
67. Harriman, G., Greenwood, J., Bhat, S., Huang, X., Wang, R., Paul, D., Tong, L., Saha, A.K., Westlin, W.F., Kapeller, R., Harwood, H.J. Jr., Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc. Natl. Acad. Sci. USA 113 (2016), E1796–E1805.
68. Harrison, S.A., Fecht, W., Brunt, E.M., Neuschwander-Tetri, B.A., Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 49 (2009), 80–86.
69. Harrison, S.A., Abdelmalek, M.F., Trotter, J.F., Paredes, A.H., Arnold, H.L., Kugelmas, M., Bashir, M.R., Ling, L., Rossi, S.J., DePaoli, A.M., et al. LBO-07 - NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. J. Hepatol. 66 (2017), S92–S93.
70. Harwood, H.J. Jr., Petras, S.F., Shelly, L.D., Zaccaro, L.M., Perry, D.A., Makowski, M.R., Hargrove, D.M., Martin, K.A., Tracey, W.R., Chapman, J.G., et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. 278 (2003), 37099–37111.
71. Henderson, S.J., Konkar, A., Hornigold, D.C., Trevaskis, J.L., Jackson, R., Fritsch Fredin, M., Jansson-Löfmark, R., Naylor, J., Rossi, A., Bednarek, M.A., et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 18 (2016), 1176–1190.
72. Herman, M.A., Samuel, V.T., The sweet path to metabolic demise: fructose and lipid synthesis. Trends Endocrinol. Metab. 27 (2016), 719–730.
73. Herzig, S., Raemy, E., Montessuit, S., Veuthey, J.L., Zamboni, N., Westermann, B., Kunji, E.R., Martinou, J.C., Identification and functional expression of the mitochondrial pyruvate carrier. Science 337 (2012), 93–96.
74. Hoehn, K.L., Turner, N., Cooney, G.J., James, D.E., Phenotypic discrepancies in acetyl-CoA carboxylase 2-deficient mice. J. Biol. Chem., 287, 2012, 15801 author reply 15802.
75. Huard, K., Londregan, A.T., Tesz, G., Bahnck, K.B., Magee, T.V., Hepworth, D., Polivkova, J., Coffey, S.B., Pabst, B.A., Gosset, J.R., et al. Discovery of selective small molecule inhibitors of monoacylglycerol acyltransferase 3. J. Med. Chem. 58 (2015), 7164–7172.
76. Hunkeler, M., Stuttfeld, E., Hagmann, A., Imseng, S., Maier, T., The dynamic organization of fungal acetyl-CoA carboxylase. Nat. Commun., 7, 2016, 11196.
77. Hwang, Y.C., Hayashi, T., Fujimoto, W.Y., Kahn, S.E., Leonetti, D.L., McNeely, M.J., Boyko, E.J., Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. Int. J. Obes. 39 (2015), 1365–1370.
78. Imamura, M., Takahashi, A., Yamauchi, T., Hara, K., Yasuda, K., Grarup, N., Zhao, W., Wang, X., Huerta-Chagoya, A., Hu, C., et al. Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. Nat. Commun., 7, 2016, 10531.
79. Imbriglio, J.E., Shen, D.M., Liang, R., Marby, K., You, M., Youm, H.W., Feng, Z., London, C., Xiong, Y., Tata, J., et al. Discovery and pharmacology of a novel class of diacylglycerol acyltransferase 2 inhibitors. J. Med. Chem. 58 (2015), 9345–9353.
80. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., Luo, G., Jones, S.A., Goodwin, B., Richardson, J.A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005), 217–225.
81. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5 (2007), 415–425.
82. Inzucchi, S.E., Maggs, D.G., Spollett, G.R., Page, S.L., Rife, F.S., Walton, V., Shulman, G.I., Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338 (1998), 867–872.
83. Irimia, J.M., Meyer, C.M., Segvich, D.M., Surendran, S., DePaoli-Roach, A.A., Morral, N., Roach, P.J., Lack of liver glycogen causes hepatic insulin resistance and steatosis in mice. J. Biol. Chem. 292 (2017), 10455–10464.
84. Itani, S.I., Ruderman, N.B., Schmieder, F., Boden, G., Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51 (2002), 2005–2011.
85. Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R.D., Tschöp, M.H., Müller, T.D., Hofmann, S.M., Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol. Metab. 6 (2017), 440–446.
86. Jensen, M.D., Role of body fat distribution and the metabolic complications of obesity. J. Clin. Endocrinol. Metab. 93:11, Suppl 1 (2008), S57–S63.
87. Jiang, G., Li, Z., Liu, F., Ellsworth, K., Dallas-Yang, Q., Wu, M., Ronan, J., Esau, C., Murphy, C., Szalkowski, D., et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J. Clin. Invest. 115 (2005), 1030–1038.
88. Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K.W., Shi, J., Brocker, C.N., Desai, D., Amin, S.G., Bisson, W.H., et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun., 6, 2015, 10166.
89. Jin, T., Weng, J., Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. Am. J. Physiol. Endocrinol. Metab. 311 (2016), E620–E627.
90. Jornayvaz, F.R., Birkenfeld, A.L., Jurczak, M.J., Kanda, S., Guigni, B.A., Jiang, D.C., Zhang, D., Lee, H.Y., Samuel, V.T., Shulman, G.I., Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl. Acad. Sci. USA 108 (2011), 5748–5752.
91. Kadowaki, T., Sekikawa, A., Murata, K., Maegawa, H., Takamiya, T., Okamura, T., El-Saed, A., Miyamatsu, N., Edmundowicz, D., Kita, Y., et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int. J. Obes. 30 (2006), 1163–1165.
92. Keating, S.E., Hackett, D.A., Parker, H.M., O'Connor, H.T., Gerofi, J.A., Sainsbury, A., Baker, M.K., Chuter, V.H., Caterson, I.D., George, J., Johnson, N.A., Effect of aerobic exercise training dose on liver fat and visceral adiposity. J. Hepatol. 63 (2015), 174–182.
93. Kelley, D.E., McKolanis, T.M., Hegazi, R.A., Kuller, L.H., Kalhan, S.C., Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 285 (2003), E906–E916.
94. Khorgami, Z., Shoar, S., Andalib, A., Aminian, A., Brethauer, S.A., Schauer, P.R., Trends in utilization of bariatric surgery, 2010-2014: sleeve gastrectomy dominates. Surg. Obes. Relat. Dis. 13 (2017), 774–778.
95. Kim, D., Kim, W.R., Nonobese fatty liver disease. Clin. Gastroenterol. Hepatol. 15 (2017), 474–485.
96. Kim, J.K., Gavrilova, O., Chen, Y., Reitman, M.L., Shulman, G.I., Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem. 275 (2000), 8456–8460.
97. Kim, J.K., Fillmore, J.J., Chen, Y., Yu, C., Moore, I.K., Pypaert, M., Lutz, E.P., Kako, Y., Velez-Carrasco, W., Goldberg, I.J., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. USA 98 (2001), 7522–7527.
98. Kim, C.W., Moon, Y.A., Park, S.W., Cheng, D., Kwon, H.J., Horton, J.D., Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. Proc. Natl. Acad. Sci. USA 107 (2010), 9626–9631.
99. Kir, S., Beddow, S.A., Samuel, V.T., Miller, P., Previs, S.F., Suino-Powell, K., Xu, H.E., Shulman, G.I., Kliewer, S.A., Mangelsdorf, D.J., FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331 (2011), 1621–1624.
100. Klein, S., Mittendorfer, B., Eagon, J.C., Patterson, B., Grant, L., Feirt, N., Seki, E., Brenner, D., Korenblat, K., McCrea, J., Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130 (2006), 1564–1572.
101. Kliewer, S.A., Mangelsdorf, D.J., Bile acids as hormones: the FXR-FGF15/19 pathway. Dig. Dis. 33 (2015), 327–331.
102. Krssak, M., Falk Petersen, K., Dresner, A., DiPietro, L., Vogel, S.M., Rothman, D.L., Roden, M., Shulman, G.I., Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42 (1999), 113–116.
103. Kumari, M., Schoiswohl, G., Chitraju, C., Paar, M., Cornaciu, I., Rangrez, A.Y., Wongsiriroj, N., Nagy, H.M., Ivanova, P.T., Scott, S.A., et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 15 (2012), 691–702.
104. Kumashiro, N., Erion, D.M., Zhang, D., Kahn, M., Beddow, S.A., Chu, X., Still, C.D., Gerhard, G.S., Han, X., Dziura, J., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. USA 108 (2011), 16381–16385.
105. Kumashiro, N., Yoshimura, T., Cantley, J.L., Majumdar, S.K., Guebre-Egziabher, F., Kursawe, R., Vatner, D.F., Fat, I., Kahn, M., Erion, D.M., et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 57 (2013), 1763–1772.
106. Ladenson, P.W., Kristensen, J.D., Ridgway, E.C., Olsson, A.G., Carlsson, B., Klein, I., Baxter, J.D., Angelin, B., Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med. 362 (2010), 906–916.
107. Lallukka, S., Yki-Järvinen, H., Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 30 (2016), 385–395.
108. Lazo, M., Solga, S.F., Horska, A., Bonekamp, S., Diehl, A.M., Brancati, F.L., Wagenknecht, L.E., Pi-Sunyer, F.X., Kahn, S.E., Clark, J.M., Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33 (2010), 2156–2163.
109. Levine, R., Fritz, I.B., The relation of insulin to liver metabolism. Diabetes 5 (1956), 209–219 discussion, 219–222.
110. Lewis, G.F., Zinman, B., Groenewoud, Y., Vranic, M., Giacca, A., Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. Diabetes 45 (1996), 454–462.
111. Lewis, M.C., Phillips, M.L., Slavotinek, J.P., Kow, L., Thompson, C.H., Toouli, J., Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes. Surg. 16 (2006), 697–701.
112. Li, S., Brown, M.S., Goldstein, J.L., Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. USA 107 (2010), 3441–3446.
113. Li, J.Z., Huang, Y., Karaman, R., Ivanova, P.T., Brown, H.A., Roddy, T., Castro-Perez, J., Cohen, J.C., Hobbs, H.H., Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 122 (2012), 4130–4144.
114. Lim, E.L., Hollingsworth, K.G., Aribisala, B.S., Chen, M.J., Mathers, J.C., Taylor, R., Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54 (2011), 2506–2514.
115. Linden, M.A., Sheldon, R.D., Meers, G.M., Ortinau, L.C., Morris, E.M., Booth, F.W., Kanaley, J.A., Vieira-Potter, V.J., Sowers, J.R., Ibdah, J.A., et al. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis. J. Physiol. 594 (2016), 5271–5284.
116. Lindquist, C., Bjørndal, B., Rossmann, C.R., Tusubira, D., Svardal, A., Røsland, G.V., Tronstad, K.J., Hallström, S., Berge, R.K., Increased hepatic mitochondrial FA oxidation reduces plasma and liver TG levels and is associated with regulation of UCPs and APOC-III in rats. J. Lipid Res. 58 (2017), 1362–1373.
117. Liu, J., McLaren, D.G., Chen, D., Kan, Y., Stout, S.J., Shen, X., Murphy, B.A., Forrest, G., Karanam, B., Sonatore, L., et al. Potential mechanism of enhanced postprandial glucagon-like peptide-1 release following treatment with a diacylglycerol acyltransferase 1 inhibitor. Pharmacol. Res. Perspect., 3, 2015, e00193.
118. Lockie, S.H., Heppner, K.M., Chaudhary, N., Chabenne, J.R., Morgan, D.A., Veyrat-Durebex, C., Ananthakrishnan, G., Rohner-Jeanrenaud, F., Drucker, D.J., DiMarchi, R., et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 61 (2012), 2753–2762.
119. Lotta, L.A., Gulati, P., Day, F.R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K.J., Eicher, J.D., Sharp, S.J., Luan, J., et al. EPIC-InterAct Consortium, Cambridge FPLD1 Consortium. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat. Genet. 49 (2017), 17–26.
120. Luukkonen, P.K., Zhou, Y., Hyötyläinen, T., Leivonen, M., Arola, J., Orho-Melander, M., Orešič, M., Yki-Järvinen, H., The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J. Hepatol. 65 (2016), 1263–1265.
121. Luukkonen, P.K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., Yki-Järvinen, H., Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64 (2016), 1167–1175.
122. Luukkonen, P.K., Zhou, Y., Nidhina Haridas, P.A., Dwivedi, O.P., Hyötyläinen, T., Ali, A., Juuti, A., Leivonen, M., Tukiainen, T., Ahonen, L., et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J. Hepatol. 67 (2017), 128–136.
123. Maciejewski, B.S., LaPerle, J.L., Chen, D., Ghosh, A., Zavadoski, W.J., McDonald, T.S., Manion, T.B., Mather, D., Patterson, T.A., Hanna, M., et al. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. Am. J. Physiol. Gastrointest. Liver Physiol. 304 (2013), G958–G969.
124. Maggs, D.G., Buchanan, T.A., Burant, C.F., Cline, G., Gumbiner, B., Hsueh, W.A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J.M., et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128 (1998), 176–185.
125. Magkos, F., Fabbrini, E., Mohammed, B.S., Patterson, B.W., Klein, S., Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 18 (2010), 1510–1515.
126. Magkos, F., Su, X., Bradley, D., Fabbrini, E., Conte, C., Eagon, J.C., Varela, J.E., Brunt, E.M., Patterson, B.W., Klein, S., Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology, 142, 2012 1444–6.e2.
127. Mahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., Eriksson, P., van't Hooft, F., TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc. Natl. Acad. Sci. USA 111 (2014), 8913–8918.
128. Mancina, R.M., Matikainen, N., Maglio, C., Söderlund, S., Lundbom, N., Hakkarainen, A., Rametta, R., Mozzi, E., Fargion, S., Valenti, L., et al. Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. J. Clin. Endocrinol. Metab. 100 (2015), E821–E825.
129. Mancina, R.M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150 (2016), 1219–1230.e6.
130. Mao, J., DeMayo, F.J., Li, H., Abu-Elheiga, L., Gu, Z., Shaikenov, T.E., Kordari, P., Chirala, S.S., Heird, W.C., Wakil, S.J., Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc. Natl. Acad. Sci. USA 103 (2006), 8552–8557.
131. Markan, K.R., Naber, M.C., Ameka, M.K., Anderegg, M.D., Mangelsdorf, D.J., Kliewer, S.A., Mohammadi, M., Potthoff, M.J., Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63 (2014), 4057–4063.
132. Martagón, A.J., Lin, J.Z., Cimini, S.L., Webb, P., Phillips, K.J., The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. PLoS ONE, 10, 2015, e0122987.
133. Mattar, S.G., Velcu, L.M., Rabinovitz, M., Demetris, A.J., Krasinskas, A.M., Barinas-Mitchell, E., Eid, G.M., Ramanathan, R., Taylor, D.S., Schauer, P.R., Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann. Surg. 242 (2005), 610–617 discussion 618–620.
134. Mayerson, A.B., Hundal, R.S., Dufour, S., Lebon, V., Befroy, D., Cline, G.W., Enocksson, S., Inzucchi, S.E., Shulman, G.I., Petersen, K.F., The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51 (2002), 797–802.
135. McCommis, K.S., Chen, Z., Fu, X., McDonald, W.G., Colca, J.R., Kletzien, R.F., Burgess, S.C., Finck, B.N., Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 22 (2015), 682–694.
136. McCommis, K.S., Hodges, W.T., Brunt, E.M., Nalbantoglu, I., McDonald, W.G., Holley, C., Fujiwara, H., Schaffer, J.E., Colca, J.R., Finck, B.N., Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 65 (2017), 1543–1556.
137. Meyers, C.D., Tremblay, K., Amer, A., Chen, J., Jiang, L., Gaudet, D., Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis., 14, 2015, 8.
138. Michelotti, G.A., Machado, M.V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 656–665.
139. Miles, J.M., Wooldridge, D., Grellner, W.J., Windsor, S., Isley, W.L., Klein, S., Harris, W.S., Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes 52 (2003), 675–681.
140. Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L.J., DeFronzo, R.A., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87 (2002), 2784–2791.
141. Miyazaki, M., Flowers, M.T., Sampath, H., Chu, K., Otzelberger, C., Liu, X., Ntambi, J.M., Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 6 (2007), 484–496.
142. Mori, Y., Murakawa, Y., Okada, K., Horikoshi, H., Yokoyama, J., Tajima, N., Ikeda, Y., Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22 (1999), 908–912.
143. Mudaliar, S., Henry, R.R., Sanyal, A.J., Morrow, L., Marschall, H.U., Kipnes, M., Adorini, L., Sciacca, C.I., Clopton, P., Castelloe, E., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology, 145, 2013 574–82.e1.
144. Nagai, Y., Yonemitsu, S., Erion, D.M., Iwasaki, T., Stark, R., Weismann, D., Dong, J., Zhang, D., Jurczak, M.J., Löffler, M.G., et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab. 9 (2009), 252–264.
145. Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J.S., Ramakrishnan, R., Ginsberg, H.N., Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest. 115 (2005), 1323–1332.
146. Nagata, N., Xu, L., Kohno, S., Ushida, Y., Aoki, Y., Umeda, R., Fuke, N., Zhuge, F., Ni, Y., Nagashimada, M., et al. Glucoraphanin ameliorates obesity and insulin resistance through adipose tissue browning and reduction of metabolic endotoxemia in mice. Diabetes 66 (2017), 1222–1236.
147. Nakae, J., Kitamura, T., Silver, D.L., Accili, D., The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 108 (2001), 1359–1367.
148. Nazare, J.A., Smith, J.D., Borel, A.L., Haffner, S.M., Balkau, B., Ross, R., Massien, C., Alméras, N., Després, J.P., Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. Am. J. Clin. Nutr. 96 (2012), 714–726.
149. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., et al., NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
150. Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G.D., Pham, T.A., Dillard-Telm, L., Tsai, S.P., Stephan, J.-P., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160 (2002), 2295–2307.
151. Nielsen, S., Guo, Z., Johnson, C.M., Hensrud, D.D., Jensen, M.D., Splanchnic lipolysis in human obesity. J. Clin. Invest. 113 (2004), 1582–1588.
152. Ntambi, J.M., Miyazaki, M., Stoehr, J.P., Lan, H., Kendziorski, C.M., Yandell, B.S., Song, Y., Cohen, P., Friedman, J.M., Attie, A.D., Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. USA 99 (2002), 11482–11486.
153. Okuma, C., Ohta, T., Tadaki, H., Hamada, H., Oda, T., Taniuchi, H., Yamanaka, K., Ishii, Y., Ohe, Y., Yata, S., et al. JTP-103237, a novel monoacylglycerol acyltransferase inhibitor, modulates fat absorption and prevents diet-induced obesity. Eur. J. Pharmacol. 758 (2015), 72–81.
154. Okuma, C., Ohta, T., Tadaki, H., Ishigure, T., Sakata, S., Taniuchi, H., Sano, R., Hamada, H., Kume, S., Nishiu, J., Kakutani, M., JTP-103237, a monoacylglycerol acyltransferase inhibitor, prevents fatty liver and suppresses both triglyceride synthesis and de novo lipogenesis. J. Pharmacol. Sci. 128 (2015), 150–157.
155. Olson, D.P., Pulinilkunnil, T., Cline, G.W., Shulman, G.I., Lowell, B.B., Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc. Natl. Acad. Sci. USA 107 (2010), 7598–7603.
156. Owen, B.M., Ding, X., Morgan, D.A., Coate, K.C., Bookout, A.L., Rahmouni, K., Kliewer, S.A., Mangelsdorf, D.J., FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20 (2014), 670–677.
157. Palmer, A.K., Kirkland, J.L., Aging and adipose tissue: potential interventions for diabetes and regenerative medicine. Exp. Gerontol. 86 (2016), 97–105.
158. Park, J.G., Xu, X., Cho, S., Hur, K.Y., Lee, M.S., Kersten, S., Lee, A.H., CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis. Sci. Rep., 6, 2016, 27938.
159. Pawlak, M., Lefebvre, P., Staels, B., Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62 (2015), 720–733.
160. Perry, R.J., Kim, T., Zhang, X.M., Lee, H.Y., Pesta, D., Popov, V.B., Zhang, D., Rahimi, Y., Jurczak, M.J., Cline, G.W., et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab. 18 (2013), 740–748.
161. Perry, R.J., Zhang, X.M., Zhang, D., Kumashiro, N., Camporez, J.P., Cline, G.W., Rothman, D.L., Shulman, G.I., Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Med. 20 (2014), 759–763.
162. Perry, R.J., Camporez, J.P., Kursawe, R., Titchenell, P.M., Zhang, D., Perry, C.J., Jurczak, M.J., Abudukadier, A., Han, M.S., Zhang, X.M., et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 160 (2015), 745–758.
163. Perry, R.J., Zhang, D., Zhang, X.-M., Boyer, J.L., Shulman, G.I., Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347 (2015), 1253–1256.
164. Perseghin, G., Price, T.B., Petersen, K.F., Roden, M., Cline, G.W., Gerow, K., Rothman, D.L., Shulman, G.I., Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N. Engl. J. Med. 335 (1996), 1357–1362.
165. Perseghin, G., Scifo, P., De Cobelli, F., Pagliato, E., Battezzati, A., Arcelloni, C., Vanzulli, A., Testolin, G., Pozza, G., Del Maschio, A., Luzi, L., Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48 (1999), 1600–1606.
166. Peter, A., Kantartzis, K., Machicao, F., Machann, J., Wagner, S., Templin, S., Königsrainer, I., Königsrainer, A., Schick, F., Fritsche, A., et al. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int. J. Obes. 36 (2012), 774–782.
167. Petersen, K.F., Hendler, R., Price, T., Perseghin, G., Rothman, D.L., Held, N., Amatruda, J.M., Shulman, G.I., 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes 47 (1998), 381–386.
168. Petersen, K.F., Laurent, D., Rothman, D.L., Cline, G.W., Shulman, G.I., Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J. Clin. Invest. 101 (1998), 1203–1209.
169. Petersen, K.F., Krssak, M., Inzucchi, S., Cline, G.W., Dufour, S., Shulman, G.I., Mechanism of troglitazone action in type 2 diabetes. Diabetes 49 (2000), 827–831.
170. Petersen, K.F., Oral, E.A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G.W., DePaoli, A.M., Taylor, S.I., Gorden, P., Shulman, G.I., Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109 (2002), 1345–1350.
171. Petersen, K.F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R.E., Shulman, G.I., Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54 (2005), 603–608.
172. Petersen, K.F., Dufour, S., Savage, D.B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G.W., Befroy, D., Zemany, L., Kahn, B.B., et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 104 (2007), 12587–12594.
173. Petersen, K.F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J.N., Zhang, X.M., Dziura, J., Lifton, R.P., Shulman, G.I., Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362 (2010), 1082–1089.
174. Petersen, M.C., Madiraju, A.K., Gassaway, B.M., Marcel, M., Nasiri, A.R., Butrico, G., Marcucci, M.J., Zhang, D., Abulizi, A., Zhang, X.-M., et al. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J. Clin. Invest. 126 (2016), 4361–4371.
175. Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang, S.A., Balderas, E., Guertin, D.A., Madden, K.L., Carpenter, A.E., Finck, B.N., Sabatini, D.M., mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146 (2011), 408–420.
176. Pingitore, P., Pirazzi, C., Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., Montalcini, T., Hedfalk, K., Romeo, S., Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim. Biophys. Acta 1841 (2014), 574–580.
177. Pocai, A., Carrington, P.E., Adams, J.R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M.E., Jiang, G., et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58 (2009), 2258–2266.
178. Potthoff, M.J., Boney-Montoya, J., Choi, M., He, T., Sunny, N.E., Satapati, S., Suino-Powell, K., Xu, H.E., Gerard, R.D., Finck, B.N., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab. 13 (2011), 729–738.
179. Potthoff, M.J., Kliewer, S.A., Mangelsdorf, D.J., Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 26 (2012), 312–324.
180. Prager, R., Wallace, P., Olefsky, J.M., Direct and indirect effects of insulin to inhibit hepatic glucose output in obese subjects. Diabetes 36 (1987), 607–611.
181. Previs, S.F., Cline, G.W., Shulman, G.I., A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo. Am. J. Physiol. 277 (1999), E154–E160.
182. Qu, X., Seale, J.P., Donnelly, R., Tissue and isoform-selective activation of protein kinase C in insulin-resistant obese Zucker rats - effects of feeding. J. Endocrinol. 162 (1999), 207–214.
183. Rabøl, R., Petersen, K.F., Dufour, S., Flannery, C., Shulman, G.I., Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc. Natl. Acad. Sci. USA 108 (2011), 13705–13709.
184. Raddatz, K., Turner, N., Frangioudakis, G., Liao, B.M., Pedersen, D.J., Cantley, J., Wilks, D., Preston, E., Hegarty, B.D., Leitges, M., et al. Time-dependent effects of Prkce deletion on glucose homeostasis and hepatic lipid metabolism on dietary lipid oversupply in mice. Diabetologia 54 (2011), 1447–1456.
185. Raff, E.J., Kakati, D., Bloomer, J.R., Shoreibah, M., Rasheed, K., Singal, A.K., Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases. J Clin Transl Hepatol 3 (2015), 9–16.
186. Ratziu, V., Harrison, S.A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al., GOLDEN-505 Investigator Study Group. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150 (2016), 1147–1159.e5.
187. Rebrin, K., Steil, G.M., Mittelman, S.D., Bergman, R.N., Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J. Clin. Invest. 98 (1996), 741–749.
188. Rebuffé-Scrive, M., Anderson, B., Olbe, L., Björntorp, P., Metabolism of adipose tissue in intraabdominal depots in severely obese men and women. Metabolism 39 (1990), 1021–1025.
189. Roden, M., Price, T.B., Perseghin, G., Petersen, K.F., Rothman, D.L., Cline, G.W., Shulman, G.I., Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97 (1996), 2859–2865.
190. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., Boerwinkle, E., Cohen, J.C., Hobbs, H.H., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40 (2008), 1461–1465.
191. Rusu, V., Hoch, E., Mercader, J.M., Tenen, D.E., Gymrek, M., Hartigan, C.R., DeRan, M., von Grotthuss, M., Fontanillas, P., Spooner, A., et al. MEDIA Consortium, SIGMA T2D Consortium. Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms. Cell 170 (2017), 199–212.e20.
192. Safadi, R., Konikoff, F.M., Mahamid, M., Zelber-Sagi, S., Halpern, M., Gilat, T., Oren, R., FLORA Group. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12 (2014), 2085–20891.e1.
193. Safar Zadeh, E., Lungu, A.O., Cochran, E.K., Brown, R.J., Ghany, M.G., Heller, T., Kleiner, D.E., Gorden, P., The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J. Hepatol. 59 (2013), 131–137.
194. Sampath, H., Flowers, M.T., Liu, X., Paton, C.M., Sullivan, R., Chu, K., Zhao, M., Ntambi, J.M., Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high fat diet-induced obesity. J. Biol. Chem. 284 (2009), 19961–19973.
195. Samuel, V.T., Shulman, G.I., Mechanisms for insulin resistance: common threads and missing links. Cell 148 (2012), 852–871.
196. Samuel, V.T., Shulman, G.I., The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Invest. 126 (2016), 12–22.
197. Samuel, V.T., Liu, Z.X., Qu, X., Elder, B.D., Bilz, S., Befroy, D., Romanelli, A.J., Shulman, G.I., Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279 (2004), 32345–32353.
198. Samuel, V.T., Liu, Z.X., Wang, A., Beddow, S.A., Geisler, J.G., Kahn, M., Zhang, X.M., Monia, B.P., Bhanot, S., Shulman, G.I., Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest. 117 (2007), 739–745.
199. Santoro, N., Zhang, C.K., Zhao, H., Pakstis, A.J., Kim, G., Kursawe, R., Dykas, D.J., Bale, A.E., Giannini, C., Pierpont, B., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55 (2012), 781–789.
200. Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., et al., NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362 (2010), 1675–1685.
201. Sanyal, A., Charles, E.D., Neuschwander-Tetri, B.A., Loomba, R., Harrison, S., Abdelmalek, M., Lawitz, E., Halegoua-DeMarzio, D., Dong, Y., Noviello, S., et al. BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study. J. Hepatol. 66 (2017), S89–S90.
202. Savage, D.B., Choi, C.S., Samuel, V.T., Liu, Z.X., Zhang, D., Wang, A., Zhang, X.M., Cline, G.W., Yu, X.X., Geisler, J.G., et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116 (2006), 817–824.
203. Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Aminian, A., Brethauer, S.A., Navaneethan, S.D., Singh, R.P., Pothier, C.E., Nissen, S.E., Kashyap, S.R., STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N. Engl. J. Med. 376 (2017), 641–651.
204. Schell, J.C., Olson, K.A., Jiang, L., Hawkins, A.J., Van Vranken, J.G., Xie, J., Egnatchik, R.A., Earl, E.G., DeBerardinis, R.J., Rutter, J., A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol. Cell 56 (2014), 400–413.
205. Schober, G., Arnold, M., Birtles, S., Buckett, L.K., Pacheco-López, G., Turnbull, A.V., Langhans, W., Mansouri, A., Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats. J. Lipid Res. 54 (2013), 1369–1384.
206. Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B.D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., Ferrannini, E., Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 56 (2013), 156–161.
207. Sharma, A.M., Staels, B., Review: Peroxisome proliferator-activated receptor gamma and adipose tissue–understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 92 (2007), 386–395.
208. Shi, Y., Cheng, D., Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E10–E18.
209. Shulman, G.I., Cellular mechanisms of insulin resistance. J. Clin. Invest. 106 (2000), 171–176.
210. Singal, A.G., Manjunath, H., Yopp, A.C., Beg, M.S., Marrero, J.A., Gopal, P., Waljee, A.K., The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am. J. Gastroenterol. 109 (2014), 325–334.
211. Sinha, R., Dufour, S., Petersen, K.F., LeBon, V., Enoksson, S., Ma, Y.-Z., Savoye, M., Rothman, D.L., Shulman, G.I., Caprio, S., Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51 (2002), 1022–1027.
212. Sisley, S., Gutierrez-Aguilar, R., Scott, M., D'Alessio, D.A., Sandoval, D.A., Seeley, R.J., Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Invest. 124 (2014), 2456–2463.
213. Smagris, E., Gilyard, S., BasuRay, S., Cohen, J.C., Hobbs, H.H., Inactivation of Tm6sf2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J. Biol. Chem. 291 (2016), 10659–10676.
214. Smith, U., Abdominal obesity: a marker of ectopic fat accumulation. J. Clin. Invest. 125 (2015), 1790–1792.
215. Smith, B.K., Ford, R.J., Desjardins, E.M., Green, A.E., Hughes, M.C., Houde, V.P., Day, E.A., Marcinko, K., Crane, J.D., Mottillo, E.P., et al. Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK-β1. Diabetes 65 (2016), 3352–3361.
216. Sofi, F., Casini, A., Mediterranean diet and non-alcoholic fatty liver disease: new therapeutic option around the corner?. World J. Gastroenterol. 20 (2014), 7339–7346.
217. Soufi, N., Hall, A.M., Chen, Z., Yoshino, J., Collier, S.L., Mathews, J.C., Brunt, E.M., Albert, C.J., Graham, M.J., Ford, D.A., Finck, B.N., Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. J. Biol. Chem. 289 (2014), 30177–30188.
218. Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L.J., Baron, M., Lucas, A., Tailleux, A., Hum, D.W., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58 (2013), 1941–1952.
219. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G.F., Holmes, A.B., Gaffney, P.R.J., Reese, C.B., McCormick, F., Tempst, P., et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279 (1998), 710–714.
220. Szendroedi, J., Yoshimura, T., Phielix, E., Koliaki, C., Marcucci, M., Zhang, D., Jelenik, T., Müller, J., Herder, C., Nowotny, P., et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl. Acad. Sci. USA 111 (2014), 9597–9602.
221. Tao, H., Zhang, Y., Zeng, X., Shulman, G.I., Jin, S., Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat. Med. 20 (2014), 1263–1269.
222. Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363 (2010), 1341–1350.
223. Ter Horst, K.W., Gilijamse, P.W., Versteeg, R.I., Ackermans, M.T., Nederveen, A.J., la Fleur, S.E., Romijn, J.A., Nieuwdorp, M., Zhang, D., Samuel, V.T., et al. Hepatic diacylglycerol-associated protein kinase Cε translocation links hepatic steatosis to hepatic insulin resistance in humans. Cell Rep. 19 (2017), 1997–2004.
224. Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W.L., Berg, T., Dore, G.J., Grønbæk, H., Sheridan, D., et al., International Liver Disease Genetics Consortium. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat. Commun., 7, 2016, 12757.
225. Tomimoto, D., Okuma, C., Ishii, Y., Kobayashi, A., Ohta, T., Kakutani, M., Imanaka, T., Ogawa, N., JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice. J. Pharmacol. Sci. 129 (2015), 51–58.
226. Tonelli, J., Li, W., Kishore, P., Pajvani, U.B., Kwon, E., Weaver, C., Scherer, P.E., Hawkins, M., Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53 (2004), 1621–1629.
227. Tong, L., Harwood, H.J. Jr., Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J. Cell. Biochem. 99 (2006), 1476–1488.
228. Uyeda, K., Repa, J.J., Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 4 (2006), 107–110.
229. Valdecantos, M.P., Pardo, V., Ruiz, L., Castro-Sánchez, L., Lanzón, B., Fernández-Millán, E., García-Monzón, C., Arroba, A.I., González-Rodríguez, Á., Escrivá, F., et al. A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatology 65 (2017), 950–968.
230. Vatner, D.F., Weismann, D., Beddow, S.A., Kumashiro, N., Erion, D.M., Liao, X.H., Grover, G.J., Webb, P., Phillips, K.J., Weiss, R.E., et al. Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. Am. J. Physiol. Endocrinol. Metab. 305 (2013), E89–E100.
231. Vatner, D.F., Majumdar, S.K., Kumashiro, N., Petersen, M.C., Rahimi, Y., Gattu, A.K., Bears, M., Camporez, J.P., Cline, G.W., Jurczak, M.J., et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc. Natl. Acad. Sci. USA 112 (2015), 1143–1148.
232. Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S.L., Diago, M., Romero-Gomez, M., Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149, 2015 367–78.e5, quiz e14–e15.
233. Viscoli, C.M., Inzucchi, S.E., Young, L.H., Insogna, K.L., Conwit, R., Furie, K.L., Gorman, M., Kelly, M.A., Lovejoy, A.M., Kernan, W.N., IRIS Trial Investigators. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J. Clin. Endocrinol. Metab. 102 (2017), 914–922.
234. Wan, M., Leavens, K.F., Hunter, R.W., Koren, S., von Wilamowitz-Moellendorff, A., Lu, M., Satapati, S., Chu, Q., Sakamoto, K., Burgess, S.C., Birnbaum, M.J., A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. Cell Metab. 18 (2013), 99–105.
235. Watanabe, M., Houten, S.M., Mataki, C., Christoffolete, M.A., Kim, B.W., Sato, H., Messaddeq, N., Harney, J.W., Ezaki, O., Kodama, T., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006), 484–489.
236. Wehmeyer, M.H., Zyriax, B.C., Jagemann, B., Roth, E., Windler, E., Schulze Zur Wiesch, J., Lohse, A.W., Kluwe, J., Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore), 95, 2016, e3887.
237. Wei, W., Dutchak, P.A., Wang, X., Ding, X., Wang, X., Bookout, A.L., Goetz, R., Mohammadi, M., Gerard, R.D., Dechow, P.C., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc. Natl. Acad. Sci. USA 109 (2012), 3143–3148.
238. Wen, W., Kato, N., Hwang, J.Y., Guo, X., Tabara, Y., Li, H., Dorajoo, R., Yang, X., Tsai, F.J., Li, S., et al. Genome-wide association studies in East Asians identify new loci for waist-hip ratio and waist circumference. Sci. Rep., 6, 2016, 17958.
239. Williams, A.L., Jacobs, S.B., Moreno-Macías, H., Huerta-Chagoya, A., Churchhouse, C., Márquez-Luna, C., García-Ortíz, H., Gómez-Vázquez, M.J., Burtt, N.P., Aguilar-Salinas, C.A., et al., SIGMA Type 2 Diabetes Consortium. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature 506 (2014), 97–101.
240. Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., Ahmed, A., Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
241. Wright, M.B., Bortolini, M., Tadayyon, M., Bopst, M., Minireview: Challenges and opportunities in development of PPAR agonists. Mol. Endocrinol. 28 (2014), 1756–1768.
242. Wueest, S., Item, F., Lucchini, F.C., Challa, T.D., Müller, W., Blüher, M., Konrad, D., Mesenteric fat lipolysis mediates obesity-associated hepatic steatosis and insulin resistance. Diabetes 65 (2016), 140–148.
243. Wynne, K., Park, A.J., Small, C.J., Patterson, M., Ellis, S.M., Murphy, K.G., Wren, A.M., Frost, G.S., Meeran, K., Ghatei, M.A., Bloom, S.R., Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54 (2005), 2390–2395.
244. Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R.A., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58 (2009), 250–259.
245. Xu, J., Murphy, S.L., Kochanek, K.D., Arias, E., Mortality in the United States, 2015. NCHS Data Brief 267 (2016), 1–8.
246. Yoshitaka, H., Hamaguchi, M., Kojima, T., Fukuda, T., Ohbora, A., Fukui, M., Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine (Baltimore), 96, 2017, e6712.
247. Younossi, Z., Henry, L., Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 150 (2016), 1778–1785.
248. Yu, C., Chen, Y., Cline, G.W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J.K., Cushman, S.W., Cooney, G.J., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277 (2002), 50230–50236.
249. Zambad, S.P., Tuli, D., Mathur, A., Ghalsasi, S.A., Chaudhary, A.R., Deshpande, S., Gupta, R.C., Chauthaiwale, V., Dutt, C., TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes Metab. Syndr. Obes. 7 (2013), 1–14.
250. Zhang, X., Yeung, D.C.Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R.L.C., Chow, W.-S., Tso, A.W.K., Lam, K.S.L., Xu, A., Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 (2008), 1246–1253.
251. Zhang, S., Wang, J., Liu, Q., Harnish, D.C., Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51 (2009), 380–388.
252. Zhang, Y., Xie, Y., Berglund, E.D., Coate, K.C., He, T.T., Katafuchi, T., Xiao, G., Potthoff, M.J., Wei, W., Wan, Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife, 1, 2012, e00065.
253. Zhang, R.N., Zheng, R.D., Mi, Y.Q., Zhou, D., Shen, F., Chen, G.Y., Zhu, C.Y., Pan, Q., Fan, J.G., APOC3 rs2070666 is associated with the hepatic steatosis independently of PNPLA3 rs738409 in Chinese Han patients with nonalcoholic fatty liver diseases. Dig. Dis. Sci. 61 (2016), 2284–2293.
254. Zhong, Y., Li, X., Yu, D., Li, X., Li, Y., Long, Y., Yuan, Y., Ji, Z., Zhang, M., Wen, J.G., et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget 6 (2015), 37758–37769.
255. Zhou, M., Wang, X., Phung, V., Lindhout, D.A., Mondal, K., Hsu, J.Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 74 (2014), 3306–3316.